Ken Griffin Regulus Therapeutics Inc. Put Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$1.79 - $2.8 $7,876 - $12,320	-4,400 Reduced 34.92%	8,200 $14,000
Q1 2024 May 15, 2024	BUY	$1.13 - $2.88 $11,864 - $30,240	10,500 Added 500.0%	12,600 $36,000
Q4 2023 Feb 14, 2024	BUY	$1.21 - $1.44 $2,420 - $2,880	2,000 Added 2000.0%	2,100 $2,000
Q2 2023 Aug 14, 2023	BUY	$0.87 - $1.75 $87 - $175	100 New	100 $0
Q4 2022 Feb 14, 2023	BUY	$1.17 - $1.85 $1,521 - $2,405	1,300 New	1,300 $1,000

53.1M

155K

34.2K

Ticker RGLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,634,400
Market Cap $21.5M
Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.